SEARCH

SEARCH BY CITATION

References

  • 1
    Carette S, McCain GA, Bell DA, Fam AG: Evaluation of amitriptyline in primary fibrositis: a double-blind, placebo-controlled study. Arthritis Rheum 29: 655659, 1986
  • 2
    Goldenberg DL, Felson DT, Dinerman H: A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29: 13711377, 1986
  • 3
    Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B: Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 18: 447451, 1991
  • 4
    Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA: A comparison of cyclobenzaprine and placebo in the management of fibrositis: a double-blind controlled study. Arthritis Rheum 31: 15351542, 1988
  • 5
    Reynolds WJ, Moldofsky H, Saskin P, Lue FA: The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 18: 452454, 1991
  • 6
    Quimby LG, Gratwick GM, Whitney CD, Block SR: A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol (suppl 16) 19: 140143, 1989
  • 7
    Caruso I, Sarzi Puttini PC, Boccassini L, Santandrea S, Locati M, Volpato R, Montrone F, Benvenuti C, Beretta A: Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 15: 154159, 1987
  • 8
    Wysenbeek AJ, Mor F, Lurie Y, Weinberger A: Imipramine for the treatment of fibrositis: a therapeutic trial. Ann Rheum Dis 44: 752753, 1985
  • 9
    Carette J, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, Bellamy N, Guimont C: Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double-blind clinical trial. Arthritis Rheum 37: 3240, 1994
  • 10
    Geller SA: Treatment of fibrositis with fluoxetine hydrochloride (Prozac). Am J Med 87: 594595, 1989
  • 11
    Wolfe F, Cathey MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23: 255259, 1994
  • 12
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160172, 1990
  • 13
    Burckhardt CS, Clark SR, Bennett RM: The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 18: 728733, 1991
  • 14
    Kaplan KH, Goldenberg DL, Galvin-Nadeau M: The impact of a meditation-based stress reduction program on fibromyalgia. Gen Hosp Psychiatry 15: 284289, 1993
  • 15
    Senn S: Crossover Trials in Clinical Research. New York, Wiley, 1993
  • 16
    Little RJA, Rubin DB: Statistical Analysis with Missing Data. New York, Wiley, 1987
  • 17
    SAS Institute, Inc.: SAS/STAT Software. Cary, NC, SAS Institute, Inc., 1989
  • 18
    Simms RW, Felson DT, Goldenberg DL: Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 18: 15581563, 1991
  • 19
    Croft P, Schollum J, Silman A: Population study of tender point counts and pain as evidence of fibromyalgia. BMJ 309: 696699, 1994
  • 20
    Urrows S, Affleck G, Tennen H, Higgins P: Unique clinical and psychological correlates of fibromyalgia tender points and joint tenderness in rheumatoid arthritis. Arthritis Rheum 37: 15131520, 1994
  • 21
    Jocobs JWG, Rasker JJ, van der Heide A, Boersma JW, de Blecourt ACE, Griep EN, van Rijswijk MH, Bijlsma JWJ: Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res 9: 105111, 1996
  • 22
    Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35: 550556, 1992
  • 23
    Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37: 15931601, 1994
  • 24
    Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 19: 104109, 1992
  • 25
    Bennett RM, Clark SR, Campbell SM, Burckhardt CS: Low levels of somatomedin-C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain. Arthritis Rheum 35: 11131116, 1992
  • 26
    Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37: 15831592, 1994
  • 27
    Griep EN, Boersma JW, de Kloet ER: Pituitary release of growth hormone and prolactin in primary FS. J Rheumatol 21: 21252130, 1994
  • 28
    Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326: 12501256, 1992
  • 29
    Carette S, Oakson G, Guimont C, Steriade M: Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 38: 12111217, 1995